medical valve News
-
First Five Patients Successfully Treated
atHeart Medical announced today the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder. The initial patients were treated by Dr. Thomas Jones, Cardiac ...
-
Colibri Heart Valve Announces Issuance of a Patent for a Pre-mounted, Pre-packaged, Sterilized Dry Heart Valve on a Delivery System
Colibri Heart Valve, LLC, a privately held medical device company, has been granted yet another patent directed to prosthetic heart valves. More particularly, today the U.S. Patent & Trademark Office granted Colibri U.S. Patent No. 8,361,144 entitled, “Percutaneously Deliverable Heart Valve Device And Methods Associated Therewith.” The patent is directed to a method of making a ...
-
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). ...
-
SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer
PARIS, France/Tampa, FL – July, 11, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately. Richardson has over 30 years of experience in the medical device industry, and an extensive ...
By SafeHeal
-
First Five Patients Successfully Treated with atHeart Medical’s Novel reSept Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you